Journal of Korean Traditional Oncology (대한암한의학회지)
- Volume 15 Issue 1
- /
- Pages.71-77
- /
- 2010
- /
- 1975-244X(pISSN)
- /
- 2765-4850(eISSN)
A case of the elderly advanced Non-small Cell Lung Cancer Patient Treated with Allergen Removed Rhus Verniciflua Stokes extract
알러젠 제거 옻나무 추출물을 투여한 고령의 진행성 비소세포폐암 환자 1례
- Park, Hyeong-Jun (Korean Traditional Medicine Cancer Center, Kyunghee East-West Neo Medical Center) ;
- An, Ji-Hye (Korean Traditional Medicine Cancer Center, Kyunghee East-West Neo Medical Center) ;
- Lee, Jin-Soo (Korean Traditional Medicine Cancer Center, Kyunghee East-West Neo Medical Center) ;
- Jung, Yee-Hong (Korean Traditional Medicine Cancer Center, Kyunghee East-West Neo Medical Center) ;
- Lee, Sang-Hun (Korean Traditional Medicine Cancer Center, Kyunghee East-West Neo Medical Center) ;
- Cheon, Seong-Ha (Dept. of Oncology/Hematology, Kyunghee East-West Neo Medical Center) ;
- Jung, Hyun-Sik (Korean Traditional Medicine Cancer Center, Kyunghee East-West Neo Medical Center) ;
- Kim, Kyung-Suk (Korean Traditional Medicine Cancer Center, Kyunghee East-West Neo Medical Center) ;
-
Choi, Won-Cheol
(Korean Traditional Medicine Cancer Center, Kyunghee East-West Neo Medical Center)
- 박형준 (경희대학교 동서신의학병원 한방암센터) ;
- 안지혜 (경희대학교 동서신의학병원 한방암센터) ;
- 이진수 (경희대학교 동서신의학병원 한방암센터) ;
- 정의홍 (경희대학교 동서신의학병원 한방암센터) ;
- 이상헌 (경희대학교 동서신의학병원 한방암센터) ;
- 전성하 (경희대학교 동서신의학병원 혈액종양내과) ;
- 정현식 (경희대학교 동서신의학병원 한방암센터) ;
- 김경석 (경희대학교 동서신의학병원 한방암센터) ;
-
최원철
(경희대학교 동서신의학병원 한방암센터)
- Received : 2010.12.07
- Accepted : 2010.12.21
- Published : 2010.12.28
Abstract
This case report documents a case in which the administration of an herbal product, an extract of the lacquer tree, Rhus verniciflua Stokes was related with a prolonged survival in a elderly advanced non-small cell lung cancer(NSCLC) patient. A 79-year-old man who had been diagnosed with advanced NSCLC refused conventional therapy and treatment with the allergen-removed Rhus verniciflua Stokes(aRVS) had continued from September 2007 to July 2010. He had survived for 35 months after the administration of aRVS and maintained good performance status with European Cooperative Oncology Group performance status(ECOG PS) of 1. This case suggests that aRVS be alternative treatment for the elderly advanced NSCLC patients.